CN Mobile Logo

Search form


Ovarian Cancer

Ovarian Cancer

A small study found that it is feasible to detect BRCA1/2 reversion mutations in circulating cell-free DNA in patients with recurrent high-grade serous ovarian cancer. Those reversion mutations can help predict poor response to therapy in these patients.

Woman who undergo bilateral removal of ovaries at the time of hysterectomy have higher risks of all-cause mortality afterward, including hospital admission for ischemic heart disease.

An analysis of Lynch syndrome–associated ovarian cancer found that the malignancy tends to present at an early stage and has a generally good prognosis.

Women with endometrioid ovarian cancer present at a younger age and with earlier stage disease than those with serous ovarian cancer, according to a new analysis. The earlier presentation resulted in better 5- and 10-year overall survival rates as well.

The FDA granted accelerated approval to rucaparib (Rubraca), a PARP inhibitor, for the treatment of women with deleterious BRCA mutation-associated ovarian cancer.

A retrospective review showed that primary cytoreductive surgery was associated with longer survival than neoadjuvant chemotherapy in women with advanced-stage epithelial ovarian cancer.

Expression of mesothelium vascular cell adhesion molecule-1 (VCAM-1) is associated with poorer overall and progression-free survival in patients with epithelial ovarian cancer, according to a retrospective analysis.


Subscribe to Ovarian Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.